AllSight
Companies · AMLX · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. (AMLX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Amylyx Pharmaceuticals, Inc. (AMLX) stock — financials & valuation

Key numbers for Amylyx Pharmaceuticals, Inc. (AMLX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 35/100 — a percentile rank of Amylyx Pharmaceuticals, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$3.6B
EV / EBITDA-21.9×
Return on equity-63.6%
ROIC-85.4%
Debt / equity0.0×
Dividend yield0.0%

Is Amylyx Pharmaceuticals, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Amylyx Pharmaceuticals, Inc.’s own financial statements and shown as context, never as advice.

Sep 8, 2026Dual-source manufacturing
Amylyx locks in avexitide manufacturing, taking $30M pre-approval capacity risk
Aug 20, 2026$472M equity raise
Amylyx raises $500M after avexitide win, adding runway but heavy dilution
Aug 18, 2026Above the bar
Amylyx clears Phase 3 LUCIDITY endpoints, strengthening avexitide’s FDA path
Aug 18, 2026Above the bar
Amylyx clears Phase 3 avexitide trial as 55% efficacy advances NDA
Aug 6, 2026
LUCIDITY readout remains on track; quarterly loss slightly missed expectations
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact